‘Why would you promote something that is less percent safer than a condom?’: Perspectives on partially effective HIV prevention technologies among key populations in South Africa

References

• AIDS Vaccine Advocacy Coalition. (2012). Achieving the end: One year and counting. Retrieved from http://www.avac.org/resource/2012-avac-report-achieving-endE280%94one-year-and-counting
   Google Scholar
• Atujuna, M., Newman, P. A., Wallace, M., Eluhu, M., Rubincam, C., Brown, B., & Bekker, L. G. (2018). Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study. PLoS One, 13(2), e0191251. doi: 10.1371/journal.pone.0191251
   PubMed Web of Science ®Google Scholar
• Auerbach, J. D., & Hoppe, T. A. (2015). Beyond ‘getting drugs into bodies’: Social science perspectives on pre-exposure prophylaxis for HIV. Journal of the International AIDS Society, 18(4 Suppl. 3), 19983.
   PubMed Web of Science ®Google Scholar
• AVAC-PrEPWatch. (2018). Country updates. Retrieved from https://www.prepwatch.org/country-updates/#
   Google Scholar
• Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V. … MTN-020–ASPIRE Study Team. (2016). Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. New England Journal of Medicine, 375, 2121–2132. doi: 10.1056/NEJMoa1506110
   PubMed Web of Science ®Google Scholar
• Bass, E. (2005). Partially effective vaccines. In P. Kahn (Ed.), AIDS vaccine handbook (pp. 59–62). New York, NY: AIDS Vaccine Advocacy Coalition.
   Google Scholar
• Bekker, L. G., & Gray, G. E. (2017). Hope for HIV control in Southern Africa: The continued quest for a vaccine. PLoS Medicine, 14(2), e1002241. doi: 10.1371/journal.pmed.1002241
   PubMed Web of Science ®Google Scholar
• Bekker, L. G., Johnson, L., Wallace, M., & Hosek, S. (2015). Building our youth for the future. Journal of the International AIDS Society, 18(2 Suppl. 1), 20027.
   PubMedGoogle Scholar
• Bekker, L. G., Rebe, K., Venter, F., Maartens, G., Moorhouse, M., Conradie, F., … Eakles, R. (2016). Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. South African Journal of HIV Medicine, 17(1), 455.
   PubMed Web of Science ®Google Scholar
• Cameron, M., Newman, P. A., Roungprakhon, S., & Scarpa, R. (2013). The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine, 31(36), 3712–3717. doi: 10.1016/j.vaccine.2013.05.089
   PubMed Web of Science ®Google Scholar
• Chakrapani, V., Newman, P. A., Singhal, N., Nelson, R., & Shunmugam, M. (2013). ‘If it’s not working, why would they be testing it?’: Mental models of HIV vaccine trials and preventive misconception among men who have sex with men in India. BMC Public Health, 13(1), 731. doi: 10.1186/1471-2458-13-731
   PubMed Web of Science ®Google Scholar
• Duerr, A., Huang, Y., Buchbinder, S., Coombs, R. W., Sanchez, J., del Rio, C. … Step/HVTN 504 Study Team. (2012). Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (step study). Journal of Infectious Diseases, 206, 258–266. doi: 10.1093/infdis/jis342
   PubMed Web of Science ®Google Scholar
• Essack, Z., Koen, J., Slack, C., Lindegger, G., & Newman, P. A. (2012). Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials. AIDS Care, 24(10), 1249–1254. doi: 10.1080/09540121.2012.656566
   PubMed Web of Science ®Google Scholar
• Fauci, A. S., Johnston, M. I., Dieffenbach, C. W., Burton, D. R., Hammer, S. M., Hoxie, J. A., … Greene, W. C. (2008). HIV vaccine research: The way forward. Science, 321(5888), 530–532. doi: 10.1126/science.1161000
   PubMed Web of Science ®Google Scholar
• Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O’Reilly, K. R., Koechlin, F. M., … Grant, R. M. (2016). Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Aids (London, England), 30(12), 1973. doi: 10.1097/QAD.0000000000001145
   PubMed Web of Science ®Google Scholar
• Global Network of People Living with HIV (GNP+). (2010). New prevention technologies: What are they and what is their relevance for people living with HIV? Retrieved from http://www.gnpplus.net/assets/wbb_file_updown/2057/NPT_Toolkit_ENG_web.pdf
   Google Scholar
• Harrison, A. (2014). HIV prevention and research considerations for women in sub-Saharan Africa: Moving toward biobehavioral prevention strategies. African Journal of Reproductive Health, 18(3 Spec No), 17–24.
   PubMed Web of Science ®Google Scholar
• Interagency Coalition on AIDS and Development. (2010). Tools, trends and new technologies in HIV prevention. Retrieved from http://www.icad-cisd.com/pdf/Tools_trends_and_new_technologies_in_HIV_prevention_EN.pdf
   Google Scholar
• Kippax, S., & Stephenson, N. (2012). Beyond the distinction between biomedical and social dimensions of HIV prevention through the lens of a social public health. American Journal of Public Health, 102(5), 789–799. doi: 10.2105/AJPH.2011.300594
   PubMed Web of Science ®Google Scholar
• Koester, K., Amico, R. K., Gilmore, H., Liu, A., McMahan, V., Mayer, K., … Grant, R. (2017). Risk, safety and sex among male PrEP users: Time for a new understanding. Culture, Health & Sexuality, 19(12), 1301–1313. doi: 10.1080/13691058.2017.1310927
   PubMed Web of Science ®Google Scholar
• Layer, E. H., Beckham, S. W., Momburi, R. B., & Kennedy, C. E. (2013). Understanding the partial protection of male circumcision for HIV prevention among women in Iringa region, Tanzania: An ethnomedical model. AIDS Care, 25(8), 1045–1050. doi: 10.1080/09540121.2012.748874
   PubMed Web of Science ®Google Scholar
• L'Engle, K., Lanham, M., Loolpapit, M., & Oguma, I. (2014). Understanding partial protection and HIV risk and behavior following voluntary medical male circumcision rollout in Kenya. Health Education Research, 29(1), 122–1230. doi: 10.1093/her/cyt103
   PubMed Web of Science ®Google Scholar
• Lombardo, A. P. (2011). Partial efficacy and the uptake of new biomedical prevention technologies. Retrieved from http://www.catie.ca/sites/default/files/pdf/NPT20partial20efficacy_EN_1.pdf
   Google Scholar
• MacPhail, C. L., Sayles, J. N., Cunningham, W., & Newman, P. (2012). Perceptions of sexual risk compensation following posttrial HIV vaccine uptake among young South Africans. Qualitative Health Research, 22(5), 668–678. doi: 10.1177/1049732311431944
   PubMed Web of Science ®Google Scholar
• McGowan, I., Cranston, R. D., Mayer, K. H., Febo, I., Duffill, K., Siegel, A., … Carballo-Diéguez, A. (2016). Project gel a randomized rectal microbicide safety and acceptability study in young men and transgender women. PLoS One, 11(6), e0158310. doi: 10.1371/journal.pone.0158310
   PubMed Web of Science ®Google Scholar
• Middelkoop, K., Bekker, L. G., Myer, L., Whitelaw, A., Grant, A., Kaplan, G., … Wood, R. (2010). Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. American Journal of Respiratory and Critical Care Medicine, 182(8), 1080–1085. doi: 10.1164/rccm.201004-0598OC
   PubMed Web of Science ®Google Scholar
• Milford, C., Rambally, L., Mantell, J. E., Kelvin, E. A., Mosery, N. F., & Smit, J. A. (2016). Healthcare providers’ knowledge, attitudes and practices towards medical male circumcision and their understandings of its partial efficacy in HIV prevention: Qualitative research in KwaZulu-Natal, South Africa. International Journal of Nursing Studies, 53, 182–189. doi: 10.1016/j.ijnurstu.2015.07.011
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. (2017). NIH and partners launch HIV vaccine efficacy study: Public-private partnership begins clinical trial in sub-Saharan Africa. Retrieved from https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-study
   Google Scholar
• Newman, P. A., Cameron, M., Roungprakhon, S., Tepjan, S., & Scarpa, R. (2016). Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: A discrete choice experiment. AIDS and Behavior, 20(11), 2588–2601. doi: 10.1007/s10461-015-1258-9
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Duan, N., Kakinami, L., & Roberts, K. J. (2008). What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine, 26(20), 2528–2536. doi: 10.1016/j.vaccine.2008.03.004
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Duan, N., Lee, S. J., Rudy, E. T., Seiden, D. S., Kakinami, L., & Cunningham, W. E. (2006). HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine, 24(12), 2094–2101. doi: 10.1016/j.vaccine.2005.11.013
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Duan, N., Rudy, E. T., & Anton, P. A. (2004). Challenges for HIV vaccine dissemination and clinical trial recruitment: If we build it, will they come? AIDS Patient Care & STDs, 18(12), 691–701. doi: 10.1089/apc.2004.18.691
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Duan, N., Rudy, E. T., Roberts, K. J., & Swendeman, D. (2004). Posttrial HIV vaccine adoption: Concerns, motivators, and intentions among persons at risk for HIV. Journal of Acquired Immune Deficiency Syndromes, 37(3), 1393–1403. doi: 10.1097/01.qai.0000127064.84325.ad
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Lee, S.-J., Duan, N., Rudy, E., Nakazono, T. K., Boscardin, J. … Cunningham, W. E. (2009a). Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (L.A. VOICES). Health Services Research, 44(6), 2167–2179. doi: 10.1111/j.1475-6773.2009.01039.x
   PubMed Web of Science ®Google Scholar
• Newman, P. A., & Logie, C. (2010). HIV vaccine acceptability: A systematic review and meta-analysis. Aids (London, England), 24(11), 1749–1756. doi: 10.1097/QAD.0b013e32833adbe8
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Logie, C., James, L., Charles, T., Maxwell, J., Salam, K., & Woodford, R. (2011). ‘Speaking the dialect’: Understanding public discourse in the aftermath of an HIV vaccine trial shutdown. American Journal of Public Health, 101(9), 1749–1758. doi: 10.2105/AJPH.2011.300208
   PubMed Web of Science ®Google Scholar
• Newman, P. A., Seiden, D. S., Roberts, K. J., Kakinami, L., & Duan, N. (2009b). A small dose of HIV? HIV vaccine mental models and risk communication. Health Education & Behavior, 36(2), 321–333. doi: 10.1177/1090198107305078
   PubMed Web of Science ®Google Scholar
• Phillips, A. N., Cambiano, V., Nakagawa, F., Ford, D., Lundgren, J. D., Roset-Bahmanyar, E., … Effelterre, T. V. (2014). Potential future impact of a partially effective HIV vaccine in a Southern African setting. PLoS One, 9(9), e107214. doi: 10.1371/journal.pone.0107214
   PubMed Web of Science ®Google Scholar
• Pitisuttithum, P., Rerks-Ngarm, S., O’Connell, R., Kim, J., & Excler, J. (2013). An HIV vaccine for South-East Asia – opportunities and challenges. Vaccine, 1(3), 348–366. doi: 10.3390/vaccines1030348
   Google Scholar
• Reardon, S. (2013). HIV vaccine raised infection risk: Biological and lifestyle differences cannot fully explain infection spike among trial participants. Retrieved from http://www.nature.com/news/hiv-vaccine-raised-infection-risk-1.13971
   Google Scholar
• Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R. … MOPH-TAVEG Investigators. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 361(23), 2209–2220. doi: 10.1056/NEJMoa0908492
   PubMed Web of Science ®Google Scholar
• Ritchie, J., & Lewis, L. (2003). Qualitative research practice: A guide for social science students and researchers. London: Sage.
   Google Scholar
• Underhill, K., Morrow, K. M., Colleran, C., Calabrese, S. K., Operario, D., Salovey, P., & Mayer, K. H. (2016). Explaining the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention: A qualitative study of message framing and messaging preferences among US men who have sex with men. AIDS and Behavior, 20(7), 1514–1526. doi: 10.1007/s10461-015-1088-9
   PubMed Web of Science ®Google Scholar
• Westercamp, M., Jaoko, W., Mehta, S., Abuor, P., Siambe, P., & Robert, C. B. (2017). Changes in male circumcision prevalence and risk compensation in the Kisumu, Kenya population 2008–2013. Journal of Acquired Immune Deficiency Syndromes, 74(2), e30–e37. doi: 10.1097/QAI.0000000000001180
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2015). Policy brief: consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: What’s new. Retrieved from http://www.who.int/iris/handle/10665/198064
   Google Scholar